LivaNovaLIVN
About: UK-based LivaNova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management and heart valve businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
Employees: 2,900
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
156% more call options, than puts
Call options by funds: $13.2M | Put options by funds: $5.14M
44% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 32
5% more funds holding
Funds holding: 231 [Q2] → 242 (+11) [Q3]
9% less repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 90
6.7% less ownership
Funds ownership: 103.09% [Q2] → 96.39% (-6.7%) [Q3]
10% less capital invested
Capital invested by funds: $3.06B [Q2] → $2.74B (-$318M) [Q3]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 2 (-3) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Needham Mike Matson 52% 1-year accuracy 64 / 122 met price target | 55%upside $75 | Buy Reiterated | 25 Nov 2024 |
Mizuho Anthony Petrone 42% 1-year accuracy 16 / 38 met price target | 45%upside $70 | Outperform Maintained | 31 Oct 2024 |
Baird David Rescott 83% 1-year accuracy 10 / 12 met price target | 49%upside $72 | Outperform Maintained | 31 Oct 2024 |
Financial journalist opinion
